Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice
Abstract Currently, only Palivizumab and Nirsevimab that target the respiratory syncytical virus (RSV) fusion protein are licensed for pre-treatment of infants. Glycoprotein-targeting antibodies may also provide protection against RSV. In this study, we generate monoclonal antibodies from mice immun...
Main Authors: | Youri Lee, Laura Klenow, Elizabeth M. Coyle, Gabrielle Grubbs, Hana Golding, Surender Khurana |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-47146-2 |
Similar Items
-
Pathobiology of Respiratory Syncytial Virus (RSV)
by: Ralph A. Tripp, et al.
Published: (2020-07-01) -
Respiratory Syncytial Virus (RSV) Update
by: Leonard R. Krilov, et al.
Published: (2022-09-01) -
Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies
by: Lotte Jacobs, et al.
Published: (2023-09-01) -
Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain
by: Jeehyun Lee, et al.
Published: (2021-11-01) -
Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections
by: Morgan D. McSweeney, et al.
Published: (2024-03-01)